303 results on '"Vamvakas L"'
Search Results
52. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: A phase I/II trial
53. Carboplatin plus gemcitabine as first-line treatment in eldelry patients with non-small-cell lung cancer: Preliminary results of a multicenter phase ii trial by the Hellenic Oncology Researsch Group (HORG)
54. A retrospective analysis regarding the parameters, which influence the administration of adjuvant chemotherapy in for elderly patients (>70years) with stage II or III colon cancer in the daily clinical practice
55. A meta-analysis of two Irinotecan-based phase III randomized trials for the efficacy and treatment tolerance in older patients with Metastatic Colorectal Cancer (MCRC)
56. A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
57. A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.
58. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
59. Paclitaxel and bevacizumab as first-line treatment in elderly women with HER-2 negative locally advanced or metastatic breast cancer: Preliminary results a multicenter phase II trial from Hellenic Oncology Research Group
60. A phase II study of the combination of bevacizumab with cytotoxic chemotherapy, as first line treatment, in older patients with advanced/metastatic NSCLC (non-squamous)
61. Cyclophosphamide and liposomal-encapsulated doxorubicin (MYOCET®) in elderly women with HER-2 negative locally advanced or metastatic breast cancer: Preliminary results of a multicenter phase II trial from the Hellenic Oncology Research Group
62. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
63. Baseline comprehensive geriatric assessment (CGA) and prediction of toxicity in elderly non-small cell lung cancer (NSCLC) patients receiving chemotherapy.
64. A phase I study of weekly oral topotecan in patients (pts) with relapsed small cell lung cancer (SCLC).
65. Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
66. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.
67. Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase III Hellenic Oncology Research Group trial.
68. Biweekly liposomal pegylated doxorubicin in elderly women with advanced breast cancer: A prospective multicenter trial focusing on tolerability and cardiotoxicity.
69. P47 Capecitabine, oxaliplatin and bevacizumab as first line treatment for elderly patients with metastatic colorectal cancer: a multicenter phase II trial from Hellenic Oncology Research Group
70. 9075 Phase I study of the combination of docetaxel (D) and pemetrexed (P) in patients with advanced unresectable or metastatic non small cell lung cancer (NSCLC)
71. 9040 Short term (2-month) survival prognostication in newly-diagnosed patients with Non-Small Cell Lung Cancer
72. A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer
73. Sequential administration of docetaxel followed by epirubicin plus cyclophosphamide versus FE75C as adjuvant chemotherapy in axillary lymph node-positive breast cancer. A subgroup analysis for patients over 65 years of age, of a randomized phase III trial of Hellenic Oncology Research Group (HORG)
74. Prognostic value of Mini Nutritional Assessment (MNA) score in elderly lung-cancer patients
75. The relationship between measures of nutritional status and Comprehensive Geriatric Assessment
76. Results of the Comprehensive Geriatric Assessment (CGA) of elderly cancer patients in an academic mediacal oncology clinic
77. CAPIRI (capecitabine, irinotecan) + bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) + bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial
78. Evaluation of mini nutritional assessment (MNA) in metastatic lung cancer patients: Correlation of laboratory values indicating malnutrition, inflammation, and cachexia with clinical data
79. Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy
80. P.40 Oral vinorelbine and gemcitabine (oVG) versus docetaxel and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis for elderly patients of a phase III randomized trial from the Hellenic Oncology Research Group (HORG)
81. P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)
82. P.19 Docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer (NSCLC): a preliminary report of a randomized phase III trial
83. Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): A randomized phase II Hellenic Oncology Research Group trial
84. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
85. O12 FOLFOXIRI versus FOLFIRI as first line treatment in metastatic colorectal cancer (MCC): a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)
86. Sequential administration of cisplatin (c), gemcitabine (g) and docetaxel (d), as first-line treatment in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract: A multicenter phase II study
87. Management and survival of frail elderly cancer patients within a Geriatric Oncology Program
88. Phase I study of gemcitabine (GEM) and premetrexed (ptx) in the treatment of advanced solid tumors
89. Comorbidity and choice of adjuvant endocrine therapy in breast cancer patients (pts) older than 70 years
90. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
91. A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors
92. Salvage Chemotherapy with Gemcitabine and Oxaliplatin in Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Phase II Study
93. A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors
94. P-509 First line treatment with docetaxel and cisplatin in non-small celllung cancer patients: A retrospective analysis
95. Docetaxel, cisplatin and gemcitabine as first line for patients with advanced/metastatic head and neck cancer
96. Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin in Patients with Advanced Solid Tumors
97. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as 1st line treatment in patients with ovarian cancer: A multicenter phase II clinical trial
98. Irinotecan (CPT-11) in Combination With Infusional 5-Fluorouracil and Leucovorin (de Gramont Regimen) as First-Line Treatment in Patients With Advanced Colorectal Cancer
99. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
100. A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.